scholarly journals Mapping endothelial functional phenotype in cancer by unveiling the kinase and phosphatase drivers

2020 ◽  
Author(s):  
Or Gadish ◽  
Elazer R. Edelman

AbstractEndothelial cells (EC) are state-dependent regulators of the tumor ecosystem: quiescent ECs promote homeostasis; proliferative ECs stimulate tumor growth. Tumors, in turn, promote pro-tumorigenic EC phenotype. We studied functional and phosphorylative transformations on EC state in cancer. Quiescent HUVECs cultured in breast cancer cell-conditioned media displayed marked elongation and impaired wound healing. Quantitative mass spectrometry identified phosphorylative regulators of this dysfunctional transformation. Growth factor receptor kinases showed decreased, rather than increased activity, suggesting that EC regulation in tumors can arise other than from classic growth-factor-mediated angiogenesis alone. Of the 152 kinases and phosphatases across 62 families, six were chosen for functional validation using pharmacologic inhibitors. Inhibiting Akt and Ptp1b restored EC regulatory state, warranting further investigation as therapeutic targets; Src inhibition, however, promoted the dysfunctional phenotype, suggesting caution for Src inhibitors as EC-regulating therapies. Mapping phosphorylative drivers reveals complex relationships between EC phenotype, transformation, and regulation, and may shed light on how existing cancer-targeting inhibitors affect tumor endothelium. Data are available via ProteomeXchange with identifier PXD020333.

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22047-e22047
Author(s):  
S. F. Matin ◽  
I. E. McCutcheon ◽  
D. S. Gombos ◽  
S. G. Waguespack ◽  
S. Wen ◽  
...  

e22047 Background: Von Hippel Lindau (VHL) disease induces vascular lesions in multiple organs. Surgical intervention is the treatment of choice. Effective, safe systemic therapy will greatly improve the quality of life of these individuals. Methods: Patients with genetically confirmed VHL were enrolled on an IRB approved trial. Eligibility criteria included retinal angiomas, hemangioblastomas (HBs) measuring at least 5mm, renal cell carcinoma (RCC) 1 to 3 cm and pancreatic neuroendocrine tumors (NETs) 1 to 3 cm. Patients received sunitinib 50mg/day for 28 days/14 days off for four cycles. Scans were performed at baseline, and after cycles two and four. A separate set of 20 formalin-fixed paraffin embedded HBs and 20 RCCs were used for laser scanning cytometry (LSC) analysis of total and phospho vascular endothelial growth factor receptor (pVEGFR) and phospho platelet derived growth factor receptor (pPDGFR) levels in tumor endothelium. Results: Twelve patients were evaluable for response and toxicity. Eight had RCCs, nine had CNS lesions, and three had pancreatic NETs. Tumor size reduction was seen in 16/19 evaluable RCC lesions (95%CI 0.60, 0.97), 3/5 NETs (95%CI 0.15, 0.95) and 6/19 HBs (95%CI 0.13, 0.57). Two patients came off study for treatment related side effects, one patient progressed on study, and two patients did not complete the scheduled course of therapy. LSC analysis demonstrated significantly lower phospho VEGFR levels in HBs when compared with RCC. The mean (SD) of pVEGFR levels in log-transformation were 11.27 (0.49) and 11.75 (0.37) for HBs and RCC respectively (p = 0.003). The mean (SD) of pVEGFR to VEGFR ratio was .21 (0.12) versus 0.37 (0.43), for HBs and RCC respsectively (p = 0.043). Conclusions: Sunitinib treatment of patients with VHL resulted in consistent decrease of RCC and NET tumor size. The discrepant response to sunitinib in RCC and HBs may be explained by differential dependence on VEGFR activation in tumor endothelium. [Table: see text]


Cells ◽  
2019 ◽  
Vol 8 (12) ◽  
pp. 1623 ◽  
Author(s):  
Kay-Dietrich Wagner ◽  
Siyue Du ◽  
Luc Martin ◽  
Nathalie Leccia ◽  
Jean-François Michiels ◽  
...  

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors, which function as transcription factors. Among them, PPARβ/δ is highly expressed in endothelial cells. Pharmacological activation with PPARβ/δ agonists had been shown to increase their angiogenic properties. PPARβ/δ has been suggested to be involved in the regulation of the angiogenic switch in tumor progression. However, until now, it is not clear to what extent the expression of PPARβ/δ in tumor endothelium influences tumor progression and metastasis formation. We addressed this question using transgenic mice with an inducible conditional vascular-specific overexpression of PPARβ/δ. Following specific over-expression of PPARβ/δ in endothelial cells, we induced syngenic tumors. We observed an enhanced tumor growth, a higher vessel density, and enhanced metastasis formation in the tumors of animals with vessel-specific overexpression of PPARβ/δ. In order to identify molecular downstream targets of PPARβ/δ in the tumor endothelium, we sorted endothelial cells from the tumors and performed RNA sequencing. We identified platelet-derived growth factor receptor beta (Pdgfrb), platelet-derived growth factor subunit B (Pdgfb), and the tyrosinkinase KIT (c-Kit) as new PPARβ/δ -dependent molecules. We show here that PPARβ/δ activation, regardless of its action on different cancer cell types, leads to a higher tumor vascularization which favors tumor growth and metastasis formation.


Sign in / Sign up

Export Citation Format

Share Document